Investor Alert: Pomerantz Law Firm Investigates Rafael Holdings, Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving Rafael Holdings, Inc. (NYSE: RFL) and its officers or directors. The investigation follows a September 30 press release from Rafael announcing that the topline results of its Phase 3 clinical trial for Trappsol Cyclo did not achieve statistical significance on the primary endpoint. On this news, Rafael's stock price dropped $0.71 per share (or 34.98%) in a single day, closing at $1.32. The firm is inviting investors to contact its legal team for potential inclusion in an upcoming class action lawsuit. Pomerantz LLP has long been recognized as one of the leading firms in securities litigation and antitrust cases. The law firm emphasizes that prior results do not guarantee similar outcomes, but it continues a legacy established over 85 years ago by Abraham L. Pomerantz.
Tickers: $RFL
Topics: clinical trial results securities fraud stock price drop